Robert M. Lorence
Boehringer Ingelheim (United States) · 88 works · 4,544 citations · h-index 29
Top works
- Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial
- Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial
- Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers
- Newcastle Disease Virus as an Antineoplastic Agent: Induction of Tumor Necrosis Factor- and Augmentation of Its Cytotoxicity2
- LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.
- Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy.
- Newcastle disease virus selectively kills human tumor cells
- Isolation and characterization of an Escherichia coli mutant lacking the cytochrome o terminal oxidase
- Properties of a copper-containing cytochrome c1aa3 complex: a terminal oxidase of the extreme thermophile Thermus thermophilus HB8.
- Complete Regression of Human Neuroblastoma Xenografts in Athymic Mice After Local Newcastle Disease Virus Therapy
- Hypophysectomy Inhibits the Synthesis of Tumor Necrosis Factor α by Rat Macrophages: Partial Restoration by Exogenous Growth Hormone or Interferon γ*
- Coulometric and spectroscopic analysis of the purified cytochrome d complex of Escherichia coli: evidence for the identification of "cytochrome a1" as cytochrome b595
- Identification of subunit I as the cytochrome b558 component of the cytochrome d terminal oxidase complex of Escherichia coli.
- LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.
- The pituitary gland is required for protection against lethal effects of Salmonella typhimurium.
- Specific overproduction and purification of the cytochrome b558 component of the cytochrome d complex from Escherichia coli
- Potentiometric analysis of the cytochromes of an Escherichia coli mutant strain lacking the cytochrome d terminal oxidase complex
- Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration
- Respiratory proteins from the extremely thermophilic aerobic bacterium, Thermus thermophilus. Purification procedures for cytochromes c552, c555,549, and c1aa3 and chemical evidence for a single subunit cytochrome aa3.
- In vivo administration of recombinant growth hormone or gamma interferon activities macrophages: enhanced resistance to experimental Salmonella typhimurium infection is correlated with generation of reactive oxygen intermediates